Disclaimer

The following content discusses the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx is evaluating the use of TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For RenovoCath’s Indications for Use and safety information, please visit IFU.

Learn more about how hospitals are using the TAMP™ therapy platform with the RenovoCath® device in oncology management, and participant experiences in the Phase III TIGeR-PaC clinical trial.*

Lakewood Ranch Pancreatic Cancer Patient Receives New Treatment

A Lakewood Ranch retiree is one of the first patients in the country to receive an experimental treatment for pancreatic cancer through a trial offered at Sarasota Memorial Hospital.

Vince Scully, 74, was diagnosed with Stage III pancreatic cancer in June, and initially underwent the standard treatment of chemotherapy and radiation. His cancer was inoperable but had not metastasized to other organs.

Dr. Kenneth Meredith, a surgical oncologist who is leading a multidisciplinary team at SMH, determined that Scully was a good candidate for the new treatment option. As part of an international trial, Scully received targeted chemotherapy delivered via a catheter inserted in his femoral artery directly into his pancreatic tumor. Doctors blocked the outflow arteries from the pancreas so that the chemo effects are localized and side effects are minimal compared with traditional treatment.

View the entire article on the Herald Tribune

RenovoRx is participating in clinical trials and the FDA has not determined the safety and or efficacy of its clinical drug development program.